Actively Recruiting
Evaluating Safety and Effects of Single-Dose MWX401 Injection in Healthy Adults and Mild Hypertension
Led by Shanghai Minwei Biotechnology Co., Ltd · Updated on 2026-09-08
46
Participants Needed
1
Research Sites
8 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are conducting a phase 1 clinical trial to evaluate the safety, tolerability, pharmacokinetics PK, pharmacodynamics PD, and immune response to a single subcutaneous dose of MWX401 Injection. The study involves healthy Chinese adults and individuals with mild primary hypertension. It aims to understand how the drug behaves in the body and its effects on blood pressure and related biomarkers. Participants will be assigned to one of five dose groups receiving different amounts of MWX401 or a placebo, all given by subcutaneous injection. The study is randomized and double-blind, meaning neither participants nor researchers know which treatment is administered. The five dose cohorts will be studied sequentially to assess safety and drug behavior. During the trial, participants will be monitored for at least 85 days to record any treatment-related adverse events and changes in blood pressure and biomarkers such as serum angiotensinogen and RAAS components. Researchers will also measure drug levels in plasma and urine up to 72 hours after dosing and evaluate immune responses. Participants will undergo regular assessments including electrocardiograms and blood pressure measurements to ensure safety and collect data.
CONDITIONS
Brief Title
Phase 1 Clinical Study of MWX401 Injection in Chinese Healthy Participants and Participants With Mild Hypertension
Research Team
W
Wanxiang Chen
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here